Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
Date:3/20/2009

boplatin are delivered to patients with escalating intravenous dosages of REOLYSIN(R). Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours such as head and neck, melanoma, lung and ovarian that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The second component of the trial is a Phase II, 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists.

An independent, confirmatory Phase II trial using the same combination of REOLYSIN(R) and carboplatin/paclitaxel for patients with head and neck cancers is currently underway in the U.S. Interim results from both the U.K. and the U.S. study formed the basis of the Phase III pivotal program now being developed for REOLYSIN(R) in combination with carboplatin/paclitaxel in this patient population.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN(R), the Compan
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  Orexigen Therapeutics, Inc. (Nasdaq: OREX ... List of Outstanding Issues (LOI) from the European Medicines ... for the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone ... drug candidate being evaluated for weight loss. ... point were adequately addressed by the Company based in ...
(Date:7/30/2014)...  AtheroNova Inc. (OTCBB: AHRO), a biotech company ... to safely regress atherosclerotic plaque and improve lipid ... CardioNova, has accomplished first dosing of subjects for ... compound, AHRO-001.  This Phase 1b trial will be ... trial completed in February 2014, in which patients ...
(Date:7/30/2014)... July 30, 2014 Vala Sciences ... U.S. Environmental Protection Agency (EPA). This new contract ... toxicity models, including tests designed to assess the ... the formation of connections between neurons (synapses), which ... and synapse formation by environmental pollutants likely contributes ...
(Date:7/29/2014)... MA (PRWEB) July 30, 2014 ... (UC) and collaboration company, is proud to announce ... account management positions in their Boston, Charleston and ... response to the increased demand for hosted solutions, ... operational efficiency and reduce cost. , SoundConnect was ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3SoundConnect Organization and Culture is Evolving 2
... July 5, 2011 Simulated Environment Concepts ... loss, wellness, and slimming equipment, announced today that the ... within the next five business days. ... Concepts (SE Concepts) stated, "We received word from Grass ...
... NEW YORK, July 4, 2011 Reportlinker.com ... is available in its catalogue: ... 2011-2021 http://www.reportlinker.com/p0567594/Stem-Cell-Technologies-World-Market-Outlook-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy ... market develop this decade? Our new report ...
... computers may rely on magnetic microprocessors that consume ... laws of physics, according to an analysis by ... silicon-based microprocessor chips rely on electric currents, or ... heat. But microprocessors employing nanometer-sized bar magnets ...
Cached Biology Technology:Simulated Environment Concepts' Research Report to be Released - Domestic Sales Force Established 2Simulated Environment Concepts' Research Report to be Released - Domestic Sales Force Established 3Stem Cell Technologies: World Market Outlook 2011-2021 2Stem Cell Technologies: World Market Outlook 2011-2021 3Stem Cell Technologies: World Market Outlook 2011-2021 4Stem Cell Technologies: World Market Outlook 2011-2021 5Stem Cell Technologies: World Market Outlook 2011-2021 6Stem Cell Technologies: World Market Outlook 2011-2021 7Stem Cell Technologies: World Market Outlook 2011-2021 8Stem Cell Technologies: World Market Outlook 2011-2021 9Stem Cell Technologies: World Market Outlook 2011-2021 10Stem Cell Technologies: World Market Outlook 2011-2021 11Stem Cell Technologies: World Market Outlook 2011-2021 12Magnetic memory and logic could achieve ultimate energy efficiency 2Magnetic memory and logic could achieve ultimate energy efficiency 3Magnetic memory and logic could achieve ultimate energy efficiency 4
(Date:7/30/2014)... treatment has been shown to relieve patients, pain. ... transmission between the peripheral and central nervous systems, ... Radiation Medicine, Chinese Academy of Medical Sciences, China ... dorsal root ganglia (DRG) to provide relief for ... 14.8, 29.6 MBq) were implanted separately into the ...
(Date:7/30/2014)... is still in its infant stage. But it is ... significance. "Amazingly often, we are findingin addition to Asian ... found in Baltic amber," explained Bonn paleontologist Professor Dr. ... the Baltic Sea region, which is almost 10,000 kilometers ... coastal regions of Mecklenburg, Poland and Belarus. The pieces ...
(Date:7/30/2014)... In a paper published online today in the journal ... Northeastern researchers Evan Kodra and Auroop Ganguly found that ... the variability in temperature extremes. For instance, while each ... those averages will also tend to fall within a ... than are currently being observed. This means that even ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2Big data confirms climate extremes are here to stay 2
... must-have gift for young female chimpanzees this holiday season might ... the finding of scientists at Harvard University and Bates College, ... carrying them around until they have offspring of their own. ... The new work by Sonya M. Kahlenberg and Richard W. ...
... to be associated with chronic fatigue syndrome is not the ... research shows that cell samples used in previous research were ... is present in the mouse genome. XMRV was first ... encephalomyelitis (ME) in a study published in October 2009, ...
... Spring Harbor, N.Y. The nucleus of a cell, which ... that are not bound by a membrane but nevertheless exist ... (CSHL) scientists has discovered that the formation of one of ... of RNA molecules, which also maintain its structural integrity. ...
Cached Biology News:Young female chimpanzees appear to treat sticks as dolls 2New research shows virus previously linked to chronic fatigue syndrome is a lab contaminant 2New research shows virus previously linked to chronic fatigue syndrome is a lab contaminant 3CSHL study finds that 2 non-coding RNAs trigger formation of a nuclear subcompartment 2CSHL study finds that 2 non-coding RNAs trigger formation of a nuclear subcompartment 3
... an inert polymer with a unique split septum ... septum caps for use with 384-well tall-chimney plates ... used in conjunction with screw or clip-down hot ... equipment 384 septum caps may be pierced ...
... . The sensitive conductivity detector CE 4710, ... the measuring cell in a thermostatted environment. ... Data processing is provided by the CE 4900 ... high pressure CE 4100 dual piston pump. ...
Sufficient reagents for 50 applications.Mitochondria Isolation Kit Reagent A, 50 ml Mitochondria Isolation Kit Reagent B, 500 l Mitochondria Isolation Kit Reagent C, 70 ml...
... is designed to allow ampicillin selection in ... driving the gene for ampicillin resistance is ... promoter. It mediates higher transcription efficiency than ... polyadenylation signal terminates the ampicillin expression. The ...
Biology Products: